Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper
International Journal of Gynecology & Obstetrics · 2026
DOI: 10.1002/ijgo.71356 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Chiara Benedetto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Sant'Anna University Hospital, Torino, Italy. Hauptthemen laut MEDLINE: Myocardial Ischemia, Cardiovascular Diseases, Estrogen Replacement Therapy, Menopause. Die Arbeit nennt 314 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Extending women's health‐span is a key challenge for the medical community. Although women live longer than men, they face a higher burden of chronic diseases, such as cardiovascular diseases (CVDs) and disabilities. Endogenous estrogens appear to benefit cardiovascular health, and their marked decline at menopause is associated with increased cardiovascular risk; conversely, poor cardiovascular health may hasten menopause onset. Systemic menopause hormone therapy (MHT) begun early—ideally soon after symptom onset and at most within 10 years of the final menstrual period—alleviates climacteric symptoms and is associated with long‐term benefits. This joint position paper between the International Federation of Gynecology and Obstetrics (FIGO) and the World Heart Federation (WHF) aims at supporting both gynecologists and cardiologists in providing a tailored and evidence‐based counseling on systemic MHT use to women with increased CVD risk or established ischemic heart disease (IHD). Women with CVD risk factors require thorough risk stratification to tailor MHT type, dose, and route. For those at high thromboembolic risk, transdermal estrogen, with micronized progesterone or dydrogesterone when needed, is considered the safest regimen. Women with established IHD may receive systemic MHT for symptom relief, provided risks and benefits are carefully reviewed. Transdermal low‐dose estrogen, alone or with micronized progesterone or dydrogesterone, is the best choice. All primary and secondary prevention measures, including statins, should be continued. Managing the most complex cases warrants the adoption of a multidisciplinary approach between cardiologists, gynecologists, internists and primary care providers to offer the best possible care. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Sant'Anna University Hospital, Torino, Italy.
- Department of Surgical Sciences, University of Torino, Torino, Italy.
- FIGO Committee on Women at Menopausal Age, FIGO, London, UK.
- The Davis Women's Heart Center, Department of Cardiology, Houston Methodist Debakey Heart and Vascular Center, Houston, Texas, USA.
- Department of Obstetrics and Gynecology, Bombay Hospital, Mumbai, India.
- Cardiology for Women, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: Chiara Benedetto, Martha Gulati, Suvarna S Khadilkar, Angela H E M Maas, Federica Frezet, Gláucia Maria Moraes de Oliveira, Andrea R Genazzani, Hema Divakar, Athena Poppas
Zitieren
APA
Benedetto, C., Gulati, M., Khadilkar, S. S., Maas, A. H. E. M., Frezet, F., de Oliveira, G. M. M., Genazzani, A. R., Divakar, H., Poppas, A., & World Heart Federation (WHF) and the International Federation of Gynecology and Obstetrics (FIGO) (2026). Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.71356
Vancouver
Benedetto C, Gulati M, Khadilkar SS, Maas AHEM, Frezet F, de Oliveira GMM, et al. Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.71356
BibTeX
@article{Benedetto2026,
author = {Benedetto, Chiara and Gulati, Martha and Khadilkar, Suvarna S and Maas, Angela H E M and Frezet, Federica and de Oliveira, Gláucia Maria Moraes and Genazzani, Andrea R and Divakar, Hema and Poppas, Athena and World Heart Federation (WHF) and the International Federation of Gynecology and Obstetrics (FIGO), World Heart Federation (WHF) and the International Federation of Gynecology and Obstetrics (FIGO)},
title = {Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
doi = {10.1002/ijgo.71356}
}
EUVIMED